HEALTHglobal
Chinese biotech startup Excalipoint banks $69M for next-gen T cell engagers
Single source
Updated 2 hours ago
First seen March 18, 2026 17:11:23Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
The funding, which ranks as one of the largest of its kind for a China-based drug startup, will support a portfolio of multifaceted antibodies the company believes to be advances over existing treatments.